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CASE REPORT
Is Rocky Mountain Spotted Fever Transmitted in Maine?
Eric Ray MD
Maine Medical Center, Department of Internal Medicine/Graduate Medical Education, Portland, ME
Introduction:  Tick-borne disease occurs worldwide, and, recently, its distribution has been changing. Rocky Mountain 
spotted fever (RMSF) is widespread across the United States and is being monitored for introduction to 
non-endemic areas.
Clinical findings:  A 65-year-old male presented to the emergency department with fevers, myalgias, arthralgias, and 
a maculopapular rash of unclear etiology. He had a history of psoriatic arthritis under treatment with 
adalimumab, as well as exposure to local ticks, but no known recent bites. Initial testing showed 
transaminitis, worsened chronic thrombocytopenia, and slight neutropenia with an absolute neutrophil 
count of 2330 cells/µL (reference value: 2400-7600 cells/µL). His tick panel was negative for Lyme, 
anaplasma, babesia, and ehrlichia. The patient was stable and discharged.
 The patient was evaluated in the clinic and found to have improving symptoms but worsening transaminitis. 
He was empirically given doxycycline, and his repeat tick panel was also negative for Lyme, anaplasma, 
babesia, and ehrlichia. Abdominal ultrasound was unremarkable, and viral serologies were negative for 
hepatitis B and C, HIV, cytomegalovirus, and Epstein-Barr virus. His subsequent testing was positive 
for Spotted Fever Group IgG. He completed empiric treatment, and his symptoms and lab abnormalities 
resolved. The case was reported to the state of Maine Center of Disease Control and Prevention.
Conclusions:  This case does not meet requirements for diagnostic confirmation of RMSF, but it illustrates the 
diagnostic considerations for tick-borne febrile illness in Maine.
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CASE PRESENTATION
A 65-year-old male presented to the emergency 
department in late August. He reported 10 days 
of fevers, myalgias, fatigue, night sweats, and 
arthralgias. He also noticed a rash on his torso, 
back, and extremities over the previous five 
days. He was being treated with adalimumab 
for psoriatic arthritis and had contracted Lyme 
disease and ehrlichiosis 12 years earlier. He had 
a mild transaminitis and worsening of chronic 
thrombocytopenia (approximately 100 000 to 72 
000/µL). Lyme antibodies were undetectable. 
Polymerase chain reaction (PCR) tests were 
negative for anaplasmosis, babesiosis, and 
ehrlichiosis. The patient was clinically stable for 
discharge.
In a clinic visit 5 days later, the patient’s fevers 
and rash had improved. He admitted frequent tick 
exposure in wooded areas but denied recent bites 
or travel. He had a faint maculopapular rash with 
satellite lesions of the upper extremities. Repeat 
labs showed worsening alanine transaminase 83 to 
261 (0-40 U/L) and aspartate transaminase 73 to 
174 (0-37 U/L). He was given empiric doxycycline 
pending further workup 16 days after the onset of 
his symptoms.
Abdominal ultrasound, creatinine kinase, and viral 
serologies were unremarkable. His repeat tick 
panels remained negative. At a follow-up clinic 
visit after 9 days of doxycycline treatment, he only 
had mild residual fatigue. The next day, testing for 
the Spotted Fever Group Antibody IgG resulted as 
1:256 (reference value <1:64) with negative IgM, 
concerning for recent or current infection. Repeat 
labs showed resolution of all prior abnormalities.
Correspondence: Eric Ray MD
Department of Internal Medicine, Maine Medical Center
22 Bramhall Street, Portland, ME 04102
eric.jason.ray@gmail.com
Diagnoses,
Interventions,
and Outcomes:
1
Ray: Is Rocky Mountain Spotted Fever Transmitted in Maine?
Published by MaineHealth Knowledge Connection, 2020
DISCUSSION
While the American dog tick (Dermacentor 
variabilis) exists in Maine, it is not known to carry 
the Rickettsia rickettsii (R. rickettsii) bacterium that 
causes Rocky Mountain spotted fever (RMSF).1 
There are no confirmed cases of RMSF within the 
state. RMSF is rarely seen and typically associated 
with travel exposure.1 In New England, the 
known endemic tick illnesses are Lyme, babesia, 
anaplasma, Borrelia miyamotoi (B. miyamotoi), and 
the increasingly recognized Powassan virus. These 
illnesses are transmitted by the blacklegged deer 
tick Ixodes scapularis.
RMSF is a reportable disease classified with the 
Spotted Fever Rickettsioses (SFR), which includes 
illnesses by R. parkeri, R. species 364D, and R. 
akari.2,3,4 These illnesses share cross-reactive 
antibodies, manifest with similar constitutional 
symptoms, and usually have an associated rash 
or eschar (most cases of R. parkeri).2 R. rickettsii 
is transmitted by the American dog tick east of the 
Rocky Mountains and on the Pacific Coast. It is the 
only SFR-linked tick in New England (Figure 1).2,5 
RMSF was first described in the Rocky Mountains, 
but 60% of cases occur in North Carolina, 
Oklahoma, Arkansas, Tennessee, and Missouri 
(Figure 2).2,6 Some tick species continue to expand 
their range due to climate change, resurgence of 
the white-tailed deer population, reforestation, and 
dispersal by birds. This expansion is evidenced by 
the northward movement of the lone star tick that 
transmits ehrlichiosis.7,8 Since 2000, the annual 
incidence of SFR has increased from 495 to 6248. 
However, in 2017, fewer than 10 cases were reported 
in Maine compared with 1439 cases of Lyme, 663 
of anaplasmosis, and 118 of babesiosis.2,7
R. rickettsii has an incubation period of 3-12 
days before manifestation of early symptoms (<5 
days), including fever, headache, malaise, and 
gastrointestinal distress. A maculopapular rash, 
which can involve palms and soles, starts 2-4 days 
after the fever. In untreated patients, late symptoms 
usually present after 5 days and include a petechial 
rash from vasculitis, organ failure, paralysis, and 
encephalopathy. These late, severe manifestations 
designate RMSF as the deadliest tick-borne illness 
worldwide. With the introduction of tetracyclines, 
the mortality rates associated with RMSF have 
declined significantly to 5-10%.2,3,9
The standard cross-reactive serological test 
for all SFR-group diseases is the indirect 
immunofluorescence antibody (IFA) for IgG against 
the R. rickettsii antigen.2 Antibodies are detectable 
7-10 days after infection. However, to diagnose a 
recent infection, acute and convalescent serologies 
obtained 2-4 weeks apart must reveal a fourfold 
increase, often to ≥1:256.2,10 Titers usually wane to 
<1:256 within a few months and are undetectable at 
one year. In some cases, they may be elevated for up 
to 4 years.10 The CDC (Centers for Disease Control 
and Prevention) deems cases as “confirmed” if 
both acute and convalescent titers reveal the 
fourfold increase that indicates seroconversion.11 
For more specific diagnosis of each SFR-group 
disease, there is upcoming expanded access to 
pan-Rickettsia PCR assays.9,11
In this patient, lab testing excluded anaplasma, 
babesia, Lyme, and ehrlichiosis. He did not have 
neurological manifestations of Powassan virus. He 
was not tested for the remaining Ixodes scapularis 
disease B. miyamotoi; however, with a rash that 
occurs in <10% of B. miyamotoi cases and the 
absence of sepsis, this finding is unlikely.12,13 While 
the single-elevated SFR IgG titer raises some 
concern for RMSF, the mild clinical course in an 
untreated patient, lack of typical rash progression 
from wrists/ankles to trunk, and late-summer timing 
of the illness broaden the differential diagnosis.2,14 
Additionally, other less-severe SFR diseases with 
cross-reactive antibodies are possible culprits, 
as are a variety of viral syndromes that may be 
represented by the transaminitis and reactive 
lymphocytosis (11%; 690/µL absolute count) in this 
patient.
While we do not propose a new endemic area of 
RMSF, the lack of widespread access to specific 
diagnostic testing obscures the distribution of each 
rickettsial disease. There is increasing recognition 
of the changing distributions in tick-borne disease 
in the Northeastern United States, including the 
northward movement of the lone star tick. Given 
the similar presentations of these illnesses, a 
careful approach to the differential diagnosis and 
confirmation of the diagnosis is essential, and it 
may help highlight changes in areas where the 
disease occurs.15
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Figure 1: Dermacentor variabilis (American Dog Tick)5 
Reproduced with permission from URI TickEncounter Resource Center
Figure 2: Cases of Rocky Mountain Spotted Fever Reported to the CDC in 20146  
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